Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2007 2
2009 1
2010 1
2011 4
2012 2
2013 2
2014 3
2015 3
2016 3
2017 4
2018 3
2019 2
2020 6
2021 3
2022 4
2023 4
2024 2
2025 11
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes.
Schnell O, Almandoz J, Anderson L, Barnard-Kelly K, Battelino T, Blüher M, Busetto L, Catrinou D, Ceriello A, Cos X, Danne T, Dayan CM, Del Prato S, Fernández-Fernández B, Fioretto P, Forst T, Gavin JR, Giorgino F, Groop PH, Harsch IA, Heerspink HJL, Heinemann L, Ibrahim M, Jadoul M, Jarvis S, Ji L, Kanumilli N, Kosiborod M, Landmesser U, Macieira S, Mankovsky B, Marx N, Mathieu C, McGowan B, Milenkovic T, Moser O, Müller-Wieland D, Papanas N, Patel DC, Pfeiffer AFH, Rahelić D, Rodbard HW, Rydén L, Schaeffner E, Spearman CW, Stirban A, Tacke F, Topsever P, Van Gaal L, Standl E. Schnell O, et al. Among authors: jadoul m. Cardiovasc Diabetol. 2025 May 2;24(1):187. doi: 10.1186/s12933-025-02700-0. Cardiovasc Diabetol. 2025. PMID: 40316962 Free PMC article.
The 10th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on December 5-6, 2024. This year, discussions about cardiovascular (CV) and kidney outcome trials centered on the recent finding …
The 10th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtu …
Chronic kidney disease-mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Ketteler M, Evenepoel P, Holden RM, Isakova T, Jørgensen HS, Komaba H, Nickolas TL, Sinha S, Vervloet MG, Cheung M, King JM, Grams ME, Jadoul M, Moysés RMA; Conference Participants. Ketteler M, et al. Among authors: jadoul m. Kidney Int. 2025 Mar;107(3):405-423. doi: 10.1016/j.kint.2024.11.013. Epub 2025 Jan 24. Kidney Int. 2025. PMID: 39864017 Free article.
Instead, future guideline efforts could consider mineral homeostasis and deranged endocrine systems in adults within a context of 2 clinical syndromes: CKD-associated osteoporosis, encompassing increased fracture risk in patients with CKD; and CKD-associated cardiovascular …
Instead, future guideline efforts could consider mineral homeostasis and deranged endocrine systems in adults within a context of 2 clinical …
Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Ku E, Del Vecchio L, Eckardt KU, Haase VH, Johansen KL, Nangaku M, Tangri N, Waikar SS, Więcek A, Cheung M, Jadoul M, Winkelmayer WC, Wheeler DC; for Conference Participants. Ku E, et al. Among authors: jadoul m. Kidney Int. 2023 Oct;104(4):655-680. doi: 10.1016/j.kint.2023.05.009. Epub 2023 May 24. Kidney Int. 2023. PMID: 37236424 Free article. Review.
The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Vivarelli M, Barratt J, Beck LH Jr, Fakhouri F, Gale DP, Goicoechea de Jorge E, Mosca M, Noris M, Pickering MC, Susztak K, Thurman JM, Cheung M, King JM, Jadoul M, Winkelmayer WC, Smith RJH; for Conference Participants. Vivarelli M, et al. Among authors: jadoul m. Kidney Int. 2024 Sep;106(3):369-391. doi: 10.1016/j.kint.2024.05.015. Epub 2024 Jun 4. Kidney Int. 2024. PMID: 38844295 Free article.
The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Shlipak MG, Tummalapalli SL, Boulware LE, Grams ME, Ix JH, Jha V, Kengne AP, Madero M, Mihaylova B, Tangri N, Cheung M, Jadoul M, Winkelmayer WC, Zoungas S; Conference Participants. Shlipak MG, et al. Among authors: jadoul m. Kidney Int. 2021 Jan;99(1):34-47. doi: 10.1016/j.kint.2020.10.012. Epub 2020 Oct 27. Kidney Int. 2021. PMID: 33127436 Free article.
Chronic kidney disease (CKD) causes substantial global morbidity and increases cardiovascular and all-cause mortality. Unlike other chronic diseases with established strategies for screening, there has been no consensus on whether health systems and governments should prio …
Chronic kidney disease (CKD) causes substantial global morbidity and increases cardiovascular and all-cause mortality. Unlike other c …
Blood pressure and volume management in dialysis: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Flythe JE, Chang TI, Gallagher MP, Lindley E, Madero M, Sarafidis PA, Unruh ML, Wang AY, Weiner DE, Cheung M, Jadoul M, Winkelmayer WC, Polkinghorne KR; Conference Participants. Flythe JE, et al. Among authors: jadoul m. Kidney Int. 2020 May;97(5):861-876. doi: 10.1016/j.kint.2020.01.046. Epub 2020 Mar 8. Kidney Int. 2020. PMID: 32278617 Free PMC article.
Blood pressure (BP) and volume control are critical components of dialysis care and have substantial impacts on patient symptoms, quality of life, and cardiovascular complications. Yet, developing consensus best practices for BP and volume control have been challenging, gi …
Blood pressure (BP) and volume control are critical components of dialysis care and have substantial impacts on patient symptoms, quality of …
Preventing chronic kidney disease and maintaining kidney health: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Ortiz A, Arreola Guerra JM, Chan JCN, Jha V, Kramer H, Nicholas SB, Pavkov ME, Wanner C, Wong LP, Cheung M, King JM, Grams ME, Jadoul M, Tuttle KR; Conference Participants. Ortiz A, et al. Among authors: jadoul m. Kidney Int. 2025 Oct;108(4):555-571. doi: 10.1016/j.kint.2025.04.005. Epub 2025 Jun 19. Kidney Int. 2025. PMID: 40536455 Free PMC article.
In contrast, maintaining kidney health and preventing CKD have received limited attention, despite their potential to save millions of lives, reduce health care costs, and lessen environmental burdens. The cardiovascular-kidney-metabolic (CKM) concept frames CKD as part of …
In contrast, maintaining kidney health and preventing CKD have received limited attention, despite their potential to save millions of lives …
Kidney Disease and Heart Failure: Recent Advances and Current Challenges: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Lam CSP, Bozkurt B, Cherney DZI, Ezekowitz JA, Jardine MJ, Khan SS, Madero M, Sarnak MJ, Ter Maaten JM, Cheung M, King JM, Grams ME, Jadoul M, Bansal N; Conference Participants. Lam CSP, et al. Among authors: jadoul m. JACC Heart Fail. 2026 Apr;14(4):102943. doi: 10.1016/j.jchf.2026.102943. Epub 2026 Mar 6. JACC Heart Fail. 2026. PMID: 41793402 Free PMC article.
Sodium-glucose cotransporter-2 inhibitors, renin-angiotensin-aldosterone system inhibitors, and emerging agents such as finerenone and glucagon-like peptide-1 receptor agonists can have benefits in both populations of patients with HF and CKD, though evidence in advanced C …
Sodium-glucose cotransporter-2 inhibitors, renin-angiotensin-aldosterone system inhibitors, and emerging agents such as finerenone an …
Kidney disease and heart failure: recent advances and current challenges: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Lam CSP, Bozkurt B, Cherney DZI, Ezekowitz JA, Jardine MJ, Khan SS, Madero M, Sarnak MJ, Ter Maaten JM, Cheung M, King JM, Grams ME, Jadoul M, Bansal N; Conference Participants. Lam CSP, et al. Among authors: jadoul m. Kidney Int. 2026 Jun;109(6):1095-1113. doi: 10.1016/j.kint.2025.10.011. Epub 2026 Mar 6. Kidney Int. 2026. PMID: 41791738 Free article.
Sodium-glucose cotransporter-2 inhibitors, renin-angiotensin-aldosterone system inhibitors, and emerging agents such as finerenone and glucagon-like peptide-1 receptor agonists can have benefits in both populations of patients with HF and CKD, though evidence in advanced C …
Sodium-glucose cotransporter-2 inhibitors, renin-angiotensin-aldosterone system inhibitors, and emerging agents such as finerenone an …
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D; SONAR Committees and Investigators. Heerspink HJL, et al. Lancet. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X. Epub 2019 Apr 14. Lancet. 2019. PMID: 30995972 Clinical Trial.
We enrolled adults aged 18-85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR) 25-75 mL/min per 1.73 m(2) of body surface area, and a urine albumin-to-creatinine ratio (UACR) of 300-5000 mg/g who had received maximum labelled or tolerated renin-angiotensin …
We enrolled adults aged 18-85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR) 25-75 mL/min per 1.73 m(2) of body sur …
62 results